TROV : Summary for TrovaGene, Inc. - Yahoo Finance

U.S. Markets close in 2 hrs 42 mins

TrovaGene, Inc. (TROV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.98-0.02 (-1.00%)
As of 1:17PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.00
Bid1.95 x 22300
Ask2.00 x 3500
Day's Range1.95 - 2.03
52 Week Range1.78 - 6.93
Avg. Volume300,611
Market Cap60.62M
PE Ratio (TTM)-1.52
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire5 hours ago

    Trovagene to Attend the 29th Annual ROTH Conference

    SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March ...

  • Accesswire27 days ago

    LD Micro Index Reconstitution as of February 1, 2017

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2017 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2017. We believe that the existence of a true microcap ...

  • PR Newswirelast month

    Publication of Trovera™ KRAS Liquid Biopsy Test Demonstrates Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response

    SAN DIEGO, Jan. 24, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced the publication of study results in Clinical Cancer Research, demonstrating the analytical and clinical performance of Trovera™ urine and blood liquid biopsy tests to quantitatively assess KRAS mutations in patients with diverse advanced cancers.  This data was also featured as a presentation at the 2017 Gastrointestinal Cancers Symposium on January 21st in San Francisco, CA. The data demonstrate the clinical utility of Trovagene's proprietary mutation-enrichment technology to detect and quantitate KRAS mutations in urine and plasma from patients with advanced cancers. This was a blinded study with prospectively collected liquid biopsy samples, and archived tissue samples with known KRAS mutation status, from 71 patients with diverse advanced cancers.